Rezulin was developed by Parke Davis, a division of Warner Lambert, to help facilitate insulin absorption for patients with Type If Diabetes.

By 1999, the Los Angeles Times reported 55 deaths prior to the July 1998 labeling change and 57 deaths after July 1998. In March 21, 2000, Rezulin was voluntarily removed from the U.S. market but only after two million prescriptions and $1.8 billion in sales.

Leave a Comment

Your email address will not be published. Required fields are marked *